GLP-1S (5mg/vial)

GLP-1S (Semaglutide) is the top-trending GLP-1 agonist in 2026 for weight loss research, mimicking incretin effects to investigate appetite suppression, glucose regulation, and metabolic health in lab models— a staple due to its widespread use in diabetes and obesity studies. For research use only. Not for human or veterinary use.